Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis.
Former economic analyses have shown that universal mass vaccination of infants against varicella using a one-dose schedule is cost-saving in Germany. In July 2006, an MMRV combination vaccine has been approved in Germany which shall be given in a two-dose schedule. We re-analysed our former analysis with the EVITA model in order to prove whether our former conclusion that universal mass vaccination against varicella is cost-saving is still valid when using a two-dose schedule vaccine. Indeed we found that universal mass vaccination of infants against varicella with a two-dose vaccine is cost-saving from societal as well as from health care perspective.
Hammerschmidt
Thomas
T
GlaxoSmithKline, Theresienhoehe 11, D-80339 Munich, Germany. thomas.hammerschmidt@gsk.com
Bisanz
Helmtrud
H
Wutzler
Peter
P
D000293:Adolescent; D019433:Chickenpox Vaccine / Q000008:administration & dosage* / Q000191:economics*; D002648:Child; D002675:Child, Preschool; D017046:Cost Savings; D005858:Germany; D006801:Humans; D017589:Immunization Programs / Q000191:economics / Q000706:statistics & numerical data; D007115:Immunization Schedule; D007223:Infant; D032541:Mass Vaccination / Q000191:economics* / Q000706:statistics & numerical data; D022542:Measles-Mumps-Rubella Vaccine / Q000008:administration & dosage* / Q000191:economics*; D018803:Models, Economic; D015233:Models, Statistical; D012680:Sensitivity and Specificity; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000191:economics
D019433:Chickenpox Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D017778:Vaccines, Combined; C050102:measles, mumps, rubella, varicella vaccine